Compare stocks

Avacta Group plc is a UK-based clinical-stage biopharmaceutical company focused on precision oncology therapies. Its core development platform, pre|CISION, uses a peptide linker designed to be cleaved by fibroblast activation protein, a protease associated with many solid tumours, with the aim of releasing cytotoxic payloads in the tumour microenvironment while reducing systemic exposure. The clinical pipeline includes faridoxorubicin (AVA6000), a tumour-activated form of doxorubicin, and AVA6103, a pre|CISION peptide drug conjugate incorporating exatecan. The company also owns the Affimer platform, comprising engineered binding proteins that can be used in therapeutic drug conjugates and diagnostic or research applications. Avacta is headquartered at Imperial College’s White City campus in London and has been transitioning to a pure-play oncology therapeutics business through the divestment of its diagnostics operations.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.